Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

Inclusion Criteria:

• Non small cell lung cancer (Squamous or non-squamous)
• At least one prior anti-cancer therapy that did not work
• ECOG Performance Scale 0-1

Exclusion Criteria:

• Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
• Active, known or suspected autoimmune disease or infection
• Prior immuno-oncology therapy
• Corticosteroids within 2 weeks of study drug administration

Other protocol defined inclusion/exclusion criteria could apply